von willebrand factor/coagulation factor viii complex (human)
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
Wilate is a plasma-derived von Willebrand Factor/Coagulation Factor VIII complex indicated for treatment and prevention of bleeding in von Willebrand disease and hemophilia A patients. It replaces deficient or dysfunctional clotting factors through intravenous administration, restoring hemostatic function in patients with inherited bleeding disorders.
Product approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team restructuring and transition planning in coming years.
Blood Coagulation Factors
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Wilate presents a career opportunity in a mature therapeutic area requiring expertise in managed care, payer negotiations, and competitive positioning. Professionals joining this product should expect focus on market defense and lifecycle extension rather than launch or rapid growth initiatives.
Worked on Wilate - von Willebrand Factor/Coagulation Factor VIII Complex (Human) at Octapharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo